A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Proof of concept; Therapeutic Use
- Sponsors Janssen Research & Development
- 08 Aug 2017 Planned number of patients changed from 134 to 100.
- 08 Aug 2017 Status changed from active, no longer recruiting to recruiting.
- 17 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2019.